Who is sponsoring NCT00456157?

NCT00456157 is sponsored by Stryker Biotech.

What drugs are being tested in NCT00456157?

Interventions in NCT00456157: Intra-articular Injection of OP-1 to affected knee.

What condition does NCT00456157 study?

NCT00456157 studies Osteoarthritis of the Knee.

Is NCT00456157 still recruiting?

NCT00456157 is currently completed. Last updated 16 June 2010.

Last reviewed 2010-06-16 · How we verify

NCT00456157: Knee OA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 1, Double-Blind, Randomized, Single Dose Escalation Safety Study of Intra-articular Osteogenic Protein-1 OP-1 in Subjects With Osteoarthritis of the Knee

Completed Phase 1 Last updated 16 June 2010

What this trial tests

Phase 1 trial testing Intra-articular Injection of OP-1 to affected knee in Osteoarthritis of the Knee in 33 participants. Completed in 1 November 2008.

Timeline

1 March 2007

1 November 2008

Quick facts

Lead sponsor	Stryker Biotech
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	single group
Masking	double
Primary purpose	treatment
Enrollment	33
Start date	1 March 2007
Estimated completion	1 November 2008
Sites	3 locations across United States

Drugs / interventions tested

Intra-articular Injection of OP-1 to affected knee — full drug profile →

Conditions studied

Osteoarthritis of the Knee — all drugs for Osteoarthritis of the Knee →

Sponsor

Stryker Biotech — full company profile →

Who can join

40 and older, any sex, with Osteoarthritis of the Knee. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Determine safety and tolerability as well as dose limiting toxicity (DLT) and maximal tolerated dose (MTD) of intraarticular OP-1

Sponsor's own description

The purpose of this research study is to investigate the safety and tolerability of OP-1 when it is injected into the knee joint of patients who have osteoarthritis on the knee.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Progress in intra-articular therapy.
Evans CH, Kraus VB, Setton LA. · · 2014 · cited 425× · PMID 24189839 · DOI 10.1038/nrrheum.2013.159
Recent advances in the treatment of osteoarthritis.
Grässel S, Muschter D. · · 2020 · cited 172× · PMID 32419923 · DOI 10.12688/f1000research.22115.1
Phase 1 safety and tolerability study of BMP-7 in symptomatic knee osteoarthritis.
Hunter DJ, Pike MC, Jonas BL, Kissin E, et al · · 2010 · cited 103× · PMID 20932341 · DOI 10.1186/1471-2474-11-232
Bioactive peptides and proteins for tissue repair: microenvironment modulation, rational delivery, and clinical potential.
Hao ZW, Zhang ZY, Wang ZP, Wang Y, et al · · 2024 · cited 24× · PMID 39639374 · DOI 10.1186/s40779-024-00576-x
The Current Status of Clinical Trials on Biologics for Cartilage Repair and Osteoarthritis Treatment: An Analysis of ClinicalTrials.gov Data.
Zhang Z, Schon L. · · 2022 · cited 21× · PMID 35546280 · DOI 10.1177/19476035221093065
Recent Advances in Small Molecule Inhibitors for the Treatment of Osteoarthritis.
Lin J, Jia S, Zhang W, Nian M, et al · · 2023 · cited 18× · PMID 36902773 · DOI 10.3390/jcm12051986
Small molecule inhibitors of osteoarthritis: Current development and future perspective.
Liu D, Li X, Zhang L, Hu B, et al · · 2023 · cited 10× · PMID 37089415 · DOI 10.3389/fphys.2023.1156913
Unraveling Osteoarthritis: Mechanistic Insights and Emerging Therapies Targeting Pain and Inflammation.
Alad M, Yousef F, Epure LM, Lui A, et al · · 2025 · cited 6× · PMID 40563514 · DOI 10.3390/biom15060874

Verify or expand the search:

Other recruiting trials for Osteoarthritis of the Knee

Currently open trials in the same condition.

NCT07302204 — Efficacy of Aerobic Exercise Versus Therapeutic Exercises on Exercise-induced Hypoalgesia in Knee Osteoarthritis · NA · recruiting
NCT06549686 — A Phase III Study of CLS2901C in Patients With Osteoarthritis of the Knee · Phase 3 · recruiting
NCT05985785 — Bone Marrow Aspirate Concentrate (BMAC) vs Corticosteroid Injection · NA · recruiting
NCT05035810 — A Pragmatic Trial to Determine the Benefit of Behaviorally Enhanced Exercise Incentives and Corticosteroid Injections in · Phase 3 · active not recruiting
NCT04992624 — Cannabinoid Interactions With Central and Peripheral Pain Mechanisms in Osteoarthritis of the Knee · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00456157 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Stryker Biotech
Last refreshed: 16 June 2010

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00456157.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing